The rising popularity of the continuous glucose monitor, which is not the same as an insulin pump, has been a huge advance in type 1 diabetes treatment, according to David Maahs, M.D., M.A., Ph.D., from Stanford University.
“Five years ago, a newly diagnosed patient would walk in, and we'd start talking about continuous glucose monitors and 90% of people didn't know what we were talking about,” David Maahs, M.D., M.A., Ph.D., from Stanford University, said in an interview. “You can put these little devices the size of a quarter on, and it'll read your glucose values every five to 15 minutes.”
This technology is especially useful for parents of school-age children with type 1 diabetes. When their child’s insulin gets too low, an alarm goes off and a notification will be sent to their phone.
Data is then sent to the insulin pump, which delivers the correct amount of insulin to the patient.
However, the insulin pump must be placed far away enough from the glucose monitor so that there is no interference. This means that patients must wear two devices with two insertion points. Maahs said that there is ongoing research to develop a two-in-one device that both monitors blood sugar and delivers insulin.
Earlier this year, Maahs and his colleagues reported findings from a pragmatic, real-world study of a comprehensive approach of managing type1 diabetes in Nature Medicine. They enrolled 133 young (median age 11) people in the Teamwork, Targets, Technology and Tight Control — 4T, for short — study. At 12 months after enrollment, the participants had an average HbA1c of 6.58% and average glucose monitoring indicator of 7.11%. Close to two-thirds (64%) meet the target HbA1c target of 7%. The study participants had an average “time in range” of 68%, which means their blood sugar levels were in the desired range 68% of the time.
Maahs is currently a pediatric endocrinology professor at Stanford University and the Associate Chair for Academic Affairs in Pediatrics at Stanford University and the Lucile Packard Children’s Hospital.
Supporting Patients with Type 1 Diabetes Through Education, Technology and Transparency
March 10th 2025Arti Masturzo, M.D., chief medical officer of CCS, spoke with MHE in this third part of a video series to share how CCS helps patients with type 1 diabetes effectively use glucose monitors and insulin pumps by providing clear guidance and troubleshooting support, recognizing that even minor errors in management can have significant health consequences.
Read More
The Benefits of 'Hands-on' Coaching for Type 1 Diabetes
March 4th 2025In this part 2 video series, Arti Masturzo, M.D., chief medical officer of CCS, shares how coaching those with type 1 diabetes can deliver both measurable health improvements such as significant reductions in A1C levels, and enhanced patient confidence by providing hands-on education and support. Masturzo also addressed how CCS collaborates with healthcare providers and insurers to integrate care, reduce fragmentation and improve adherence to monitoring and treatment through AI-driven efforts.
Read More